Arcus Biosciences, Inc.
RCUS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $1 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 120.5% | 4.5% | -70.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -104.3% | -248.7% | -230.4% | 15.4% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -109.7% | -262.4% | -238.4% | 13.8% |
| EPS Diluted | -3.14 | -4.15 | -3.71 | 0.71 |
| % Growth | 24.3% | -11.9% | -622.5% | – |
| Operating Cash Flow | -$0 | -$0 | $0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | $0 | -$0 |